Having trouble accessing articles? Reset your cache.

Afinitor everolimus: Additional Phase III data

Additional data from the double-blind, international Phase III RADIANT-2 trial in 429 patients with advanced carcinoid tumors showed that 10 mg once-daily oral Afinitor plus Sandostatin

Read the full 264 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE